Encouraged by early clinical evidence,AstraZeneca PLC now plans a randomized, global clinical trial to test whether the BTK inhibitor Calquence (acalabrutinib) can be used to treat the exaggerated and deadly immune response, or so-called cytokine storm, linked with COVID-19 infection in severely ill patients.
Called CALAVI, the study has been designed in record time and is based on early clinical data with Calquence showing that a decrease in inflammation caused by BTK inhibition appears to
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?